Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therapy Areas

Cardiovascular

Set Alert for Cardiovascular

Latest From Cardiovascular

Kancera Targets COVID-19 With Fractalkine Inhibitor

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

Clinical Trials Companies

MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing

The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.

Clinical Trials Cardiovascular

AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure

AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.

Pricing Strategies Cardiovascular

AstraZeneca Will Test More Assets Against COVID-19

AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.

Clinical Trials Companies

Bayer Adds Up COVID-19 Pluses and Minuses In Q1

Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.

Sales & Earnings Coronavirus COVID-19

Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain

First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.

Business Strategies Legal Issues
See All

CNS

Set Alert for CNS

Latest From Neurology

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.

Approvals Neurology

Roche Touts Safety Profile For NMOSD Drug Satralizumab

With Alexion's Soliris already approved, and Viela's inebilizumab within touching distance of an FDA green light, Roche is highlighting the safety profile of its investigational neuromyelitis optica spectrum disorder drug satralizumab.

Neurology Rare Diseases

COVID-19 Hits Merck KGaA's MS Drug Mavenclad

The lockdowns caused by coronavirus has led to significant decline of multiple sclerosis patients getting to see neurologists and getting treatment. It has also reduced the number of treatment switches and Merck's drug Mavenclad is suffering as a consequence.

Sales & Earnings Coronavirus COVID-19

Lundbeck ‘Phases’ US Launch Of Long-Acting Vyepti In Migraine

Lundbeck adapted its launch strategy for its quarterly injectable migraine therapy Vyepti because of the COVID-19 pandemic, becoming more virtual, and payer responses have been encouraging.

Sales & Earnings Neurology

Newron STARS Fade With Sarizotan Failure

Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.

Rare Diseases Clinical Trials

China's First Alzheimer's Drug Enters US Trials To Much Fanfare

China's first domestically developed Alzheimer’s drug inches closer to US market as FDA approves trials with Green Valley's GV-971.

Clinical Trials Neurology
See All

Immunology

Set Alert for Immunology

Latest From Immune Disorders

Kadmon’s ROCKstar Is Rising On GvHD Therapy Data

Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.

Clinical Trials Companies

Kancera Targets COVID-19 With Fractalkine Inhibitor

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

Clinical Trials Companies

Sweden’s Affibody Inks Inmagene China R&D Pact

Swedish biotech Affibody hopes an R&D alliance with China-based Inmagene Biopharmaceuticals will speed development of its lead compound for auto-immune diseases.

Deals Immune Disorders

Cash-Rich PureTech Displays Resilience In Troubled Times

PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.

Commercial Companies

Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis

Pfizer’s next-generation JAK1 inhibitor, abrocitinib, continues to show beneficial effects in atopic dermatitis (eczema), in the JADE COMPARE study, comparable to the positive control dupilumab and, in the case of itch, with a faster onset at the higher dose.

Dermatology Clinical Trials

For Drugs That Increase Risk Of Infection, More Questions Than Answers In The Coronavirus Era

Autoimmune disease drugs ranging from Humira to Cosentyx to Tremfya to Xeljanz carry warnings about increased risk of infections. This raises new questions in the novel coronavirus outbreak.

Coronavirus COVID-19 Immune Disorders
See All

Infectious

Set Alert for Infectious Diseases

Latest From Infectious Diseases

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

Coronavirus COVID-19 BioPharmaceutical

Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication

Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.

Deals Coronavirus COVID-19

Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition

While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.

Coronavirus COVID-19 Companies

Coronavirus Update: WHO Suspends Hydroxychloroquine Trial, Novavax Launches Phase I/II Vaccine Study

Mounting evidence that President Trump's 'game changer' does more harm than good for COVID-19 patients. Novovax and Medicago among the latest vaccine developers to report progress.

Coronavirus COVID-19 Clinical Trials

Stockwatch: Reading The Entrails Of Biotech Vaccine Development

As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.

Stockwatch Vaccines

Kancera Targets COVID-19 With Fractalkine Inhibitor

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

Clinical Trials Companies
See All

Metabolic

Set Alert for Metabolic

Latest From Metabolic Disorders

US Medicare Insulin Demo Could Expand To Other Drugs

Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.

Medicare Pricing Debate

Hanmi In Tough Spot After Sanofi Efpeglenatide U-Turn

Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.

South Korea Deals

Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts

Novo Nordisk said late stage clinical trials near completion would not be hit by the pandemic but that delays to other stage studies were likely, and new ones were now “on hold.”

Clinical Trials Commercial

Taisho Deal Gives BioAge First Clinical Asset

Private US venture moves into the clinic with early-stage asset from Japanese partner with potential in aging disorders.

Commercial Deals

AstraZeneca Will Test More Assets Against COVID-19

AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.

Clinical Trials Companies

Kintai, Studying The Enteric Signaling Pathway, Is Looking For Partners

Emerging Company Profile: The start-up, funded by Flagship Pioneering, is developing small molecules across multiple therapeutic areas, based on a discovery platform exploring the microbiome, gut immune system and enteric nervous system.

StartUps and SMEs Platform Technologies
See All

Oncology

Set Alert for Oncology

Latest From Cancer

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

United States Approvals

Novartis Oncology Head Discusses Cancer Care Challenge With COVID-19

Susanne Schaffert tells Scrip that policies of prioritizing coronavirus treatment to the detriment of cancer care was a worrying move that is negatively impacting survival and mortality.

Cancer Coronavirus COVID-19

Post-IPO Zentalis Plows New Ground With China Oncology Venture

US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio. 

China Business Strategies

A Considerable Setback For Cancer Trials Because Of COVID-19, IQVIA/CRI Survey Finds

Patient enrollment in clinical trials for cancer drugs was "severely" affected by the COVID-19 pandemic, according to a report published in Nature Reviews Drug Discovery

Clinical Trials Coronavirus COVID-19

AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer

Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.

Cancer Approvals

ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer

Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.

ASCO Clinical Trials
See All

Respiratory

Set Alert for Respiratory

Latest From Respiratory

Kancera Targets COVID-19 With Fractalkine Inhibitor

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

Clinical Trials Companies

Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial

Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.    

Coronavirus COVID-19 Clinical Trials

Can Glenmark’s Triple Therapy Combo Move COPD Treatment Needle?

Glenmark rolls out three-in-one inhaler therapy for COPD in India and hopes to address challenges faced by patients suffering from the severe form of the disease. Some early physician outlook appears mixed for the new combination in a segment where leading respiratory player Cipla has an established product.

Commercial Strategy

Israeli COVID-19 Candidate Vaccine Gets Crowdfunding Support

Crowd-funding venture capital platform OurCrowd is leading a $12m investment in the newly formed MigVax Corp to fund development of a potential COVID-19 vaccine whose discovery was a by-product of an avian virus vaccine researchers were already working on for the poultry industry.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: Two UK-Backed Vaccines Progress, Cross-Industry Database Launched, Roche's Schwan On COVID-19 Impact

Plus: Korea's Dong Wha readies potent antiviral for trials, and Pharming's candidate shows promise in compassionate use.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: Alexion Tests Ultomiris in ARDS

More Phase III trials announced from Alexion and Novartis, while Karyopharm investigates potential of repurposed cancer therapy.

Coronavirus COVID-19 Companies
See All
UsernamePublicRestriction

Register